Warp Sciences Raises $215M in Funding led by Lightspeed

Warp Sciences, a San Francisco, CA-based provider of a domestic chemistry contract research organization (CRO) platform, has raised $215 million in a funding round led by Lightspeed.

The round included Premji Invest, Mayfield, IVP, Lux, Conviction, Menlo Ventures, 01 Advisors, Standard, Lowercarbon Capital, Gigascale Capital, Angular Ventures, Scribble Ventures, Uncork Capital, Innovation Endeavors, Matter VP, Zero Shot Fund, SignalFire, Moxxie Ventures, and individual angel investors.

The company will use the funding to build chemistry laboratories in the United States, improve its AI and robotics capabilities, expand its research and engineering teams, and support the discovery of new medicines.

What is Warp Sciences?

Warp Sciences is building a chemistry contract research organization (CRO) that combines experienced chemists, artificial intelligence, and robotics to help research teams make and test molecules used in drug discovery.

Read More:Health Care Startup BioStack Raises $9.5M in Seed Funding

Its goal is to help scientists move from designing a molecule to testing it more quickly. The company plans to use data from physical experiments to train better AI models, which can then support more capable and automated laboratory operations.

Warp Sciences will initially focus on lead optimization analog synthesis. This process involves making variations of a molecule so scientists can compare their properties and identify promising drug candidates.

How Much Funding Has Warp Sciences Raised?

Warp Sciences has raised $215 million in its latest funding round. The company has not disclosed details of any previous funding rounds or its total funding before this investment.

Who Invested in Warp Sciences’ Funding Round?

The round included Premji Invest, Mayfield, IVP, Lux, Conviction, Menlo Ventures, 01 Advisors, Standard, Lowercarbon Capital, Gigascale Capital, Angular Ventures, Scribble Ventures, Uncork Capital, Innovation Endeavors, Matter VP, Zero Shot Fund, SignalFire, Moxxie Ventures, and individual angel investors.

Why the Funding Matters

Warp Sciences will use the fresh capital to establish US-based chemistry laboratories and develop its AI-driven research and robotics automation capabilities. It also plans to expand its research and engineering teams.

The company aims to improve the speed and efficiency of early-stage drug discovery by helping scientists produce and test more molecular variations.

Who founded Warp Sciences?

Warp Sciences was founded in 2026 by Kevin Weil. The company is based in San Francisco, California.

It is building laboratory infrastructure for research teams developing new medicines. Rather than developing its own drug pipeline, Warp Sciences plans to provide the chemistry research capabilities that other scientific teams need.

“AI has dramatically accelerated software engineering and mathematics, but it has yet to make the same impact in the physical sciences,” said Kevin Weil, co-founder and CEO of Warp Sciences. “Chemistry and biology move forward when you make something, test it and learn from the result. If we want to build more capable AI for science, we need to generate real-world data at scale.

“I’ve worked with overseas chemistry partners that delivered speed and value, but I still worried about protecting the intellectual property behind our programs,” said Sol Reisberg, co-founder, and chief scientific officer of Warp Sciences.

Market and Business Growth

Warp Sciences is entering the chemistry research services market, where pharmaceutical, and biotechnology companies rely on external providers to conduct experiments and support drug development.

The company sees an opportunity to combine laboratory expertise with AI and robotics to improve how experiments are performed. Its model is designed to use data generated by physical experiments to improve AI systems, helping laboratories become more capable over time.

Warp Sciences aims to build domestic research capacity, but it has not disclosed customer numbers, revenue figures, or completed laboratory milestones.

What Happens Next?

Warp Sciences plans to build its US-based chemistry labs, advance AI and robotics automation, and expand its research and engineering teams.

Its initial focus will be lead optimization analog synthesis, helping scientists make and test molecular variations during drug discovery. Over time, the company aims to use experimental data to improve its AI models and increase laboratory automation.

Read More:Maxinsights Raises $30M in Seed Funding Led by Peak XV